The significant outperformance of Vertex Pharmaceuticals compared to the market, as evidenced by its 18.17% average annual return over 5 years, suggests a strong growth trajectory. This performance, coupled with a substantial market capitalization of $109.27 billion, indicates a robust financial health and operational success, likely leading to continued investor confidence and potential stock price appreciation in the short term.